The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Stents

  • If the problem of late thrombosis within the stent can be overcome, intracoronary irradiation with iridium-192 may become a useful approach to the treatment of in-stent restenosis [1].
  • Later, however, there was a significant decrease in the minimal luminal diameter and a significant increase in the stenosis of the segment with the stent (1.68 +/- 1.78 mm and 48 +/- 34 percent at follow-up) [2].
  • This study presents a patient with clinical resolution of the Budd-Chiari syndrome after placement of expandable metallic stents in the inferior vena cava and hepatic veins [3].
  • Allergic reactions to nickel and molybdenum released from stents may be one of the triggering mechanisms for in-stent restenosis [4].
  • The effect on the progression of renal failure was analysed in 23 patients by comparison of the reciprocal slopes of serum creatinine versus time plots before and after stent placement [5].

Psychiatry related information on Stents

  • Macroscopic disorientation of the structure of the 2 over 2 + 1 braided self-reinforced polylactic acid polymer stents began before 1 month, while 1 over 1 braided stents retained their construction [6].
  • Patients who do not respond to medical therapy or do not wish to take anti-anginal drugs and whose life style is limited because of anginal symptoms should be offered percutaneous revascularization procedures with or without stent placement or coronary bypass surgery [7].

High impact information on Stents

  • Late thrombosis occurred in irradiated patients only after the discontinuation of oral antiplatelet therapy (with ticlopidine or clopidogrel) and only in patients who had received new stents at the time of radiation treatment [1].
  • The cumulative incidence of death, reinfarction, or stroke at six months was lower in the stent group than in the alteplase group (8.5 vs. 23.2 percent. P=0.02; relative risk, 0.34; 95 percent confidence interval, 0.13 to 0.88) [8].
  • METHODS: We designed a multicenter study to compare primary angioplasty with angioplasty accompanied by implantation of a heparin-coated Palmaz-Schatz stent [9].
  • METHODS: Of 1965 patients who underwent coronary stenting at 50 centers, 1653 (84.1 percent) met angiographic criteria for successful placement of the stent and were randomly assigned to one of three regimens: aspirin alone (557 patients), aspirin and warfarin (550 patients), or aspirin and ticlopidine (546 patients) [10].
  • Serum creatinine levels did not change significantly after successful stent implantation in patients with previously impaired renal function [11].

Chemical compound and disease context of Stents


Biological context of Stents

  • BACKGROUND: This study was performed to analyze the influence of either aspirin, ticlopidine, or their combination on platelet activation and aggregation parameters after stent implantation [17].
  • CONCLUSIONS: Renal artery stent revascularization in the presence of normal or mildly impaired renal function had a beneficial effect on blood pressure control and a nondeleterious effect on renal function [18].
  • OBJECTIVES: The goal of this study was to identify differences in shear-induced platelet aggregation (SIPA) between patients who did or did not experience subacute stent thrombosis (SAT) [19].
  • METHODS: Two hundred and forty-four patients with single vessel disease received either a bare metal Conor stent (n = 53) or one of six different release formulations that varied in dose (10 or 30 microg) and elution release kinetics (first order, zero order), direction (abluminal, luminal), and duration (5, 10, and 30 days) [20].
  • Reconstruction of stenotic or occluded iliofemoral veins and inferior vena cava using intravascular stents: re-establishing access for future cardiac catheterization and cardiac surgery [21].

Anatomical context of Stents

  • After successful placement of Palmaz-Schatz coronary-artery stents, 257 patients were randomly assigned to receive antiplatelet therapy (ticlopidine plus aspirin) and 260 to receive anticoagulant therapy (intravenous heparin, phenprocoumon, and aspirin) [22].
  • The stent shunt was successfully placed in all patients and reduced the pressure gradient between the portal vein and the inferior vena cava by an average of 63 percent [23].
  • RESULTS: In the group that received a stent plus abciximab, the median size of the final infarct was 14.3 percent of the left ventricle (25th and 75th percentiles, 6.8 and 24.5 percent), as compared with a median of 19.4 percent (25th and 75th percentiles, 7.9 and 34.2 percent) in the alteplase group (P=0.02) [8].
  • Fifteen cholesterol-fed rabbits with preexisting iliac arterial lesions induced by balloon deendothelialization were instrumented in one iliac artery with a 2.0-mm diameter stent after balloon dilatation; the contralateral iliac lesion was treated by dilatation only to serve as a control [24].
  • The neointima of the low-activity (0.15- and 0.5-microCi) stents was composed of smooth muscle cells and matrix with complete endothelialization of the luminal surface [25].

Associations of Stents with chemical compounds

  • Survival for at least one year was associated with a patient's being under 60 years of age, having a serum bilirubin level before placement of the stent shunt of less than 1.3 mg per deciliter (22 mumol per liter), and having a complete response [23].
  • However, these studies were performed prior to the widespread use of platelet glycoprotein IIb/IIIa inhibitors and intracoronary stents [26].
  • CONCLUSION: Adjunctive eptifibatide therapy during coronary stent implantation provides benefit through 6-month follow-up [27].
  • CONCLUSIONS: Despite differences between women and men in baseline characteristics, the benefit of an early invasive strategy incorporating tirofiban and intracoronary stents was similar in women and men and was enhanced in women presenting with markers of increased risk [26].
  • Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention [28].

Gene context of Stents

  • Before stent insertion, plasma IL-6 concentrations were detectable (above 5 ng/l) in 17 (68%) patients [29].
  • IFNG T874A, IFNGR1 C-56T and IFNGR2 A839G genotypes were determined in a consecutive series of patients (n=2591) that had been treated with coronary stents [30].
  • CD40-CD40 ligand interaction is involved in the inflammatory pathogenesis of atherosclerosis but clinical data about its role in stent restenosis are still limited [31].
  • INTRODUCTION: Delivery of vascular endothelial growth factor (VEGF) protein or gene transfer has been shown to accelerate re-endothelialization and attenuate neointimal hyperplasia in various arterial injury models, including balloon injury, stent implantation, and vein grafts [32].
  • However, a decrease in PCNA staining was observed from tissue sections of venous segments cultured with TNF-alpha antibody eluting stents [33].

Analytical, diagnostic and therapeutic context of Stents


  1. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. Leon, M.B., Teirstein, P.S., Moses, J.W., Tripuraneni, P., Lansky, A.J., Jani, S., Wong, S.C., Fish, D., Ellis, S., Holmes, D.R., Kerieakes, D., Kuntz, R.E. N. Engl. J. Med. (2001) [Pubmed]
  2. Angiographic follow-up after placement of a self-expanding coronary-artery stent. Serruys, P.W., Strauss, B.H., Beatt, K.J., Bertrand, M.E., Puel, J., Rickards, A.F., Meier, B., Goy, J.J., Vogt, P., Kappenberger, L. N. Engl. J. Med. (1991) [Pubmed]
  3. Expandable venous stents for treatment of the Budd-Chiari syndrome. Lopez, R.R., Benner, K.G., Hall, L., Rösch, J., Pinson, C.W. Gastroenterology (1991) [Pubmed]
  4. Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis. Köster, R., Vieluf, D., Kiehn, M., Sommerauer, M., Kähler, J., Baldus, S., Meinertz, T., Hamm, C.W. Lancet (2000) [Pubmed]
  5. Effect of renal-artery stenting on progression of renovascular renal failure. Harden, P.N., MacLeod, M.J., Rodger, R.S., Baxter, G.M., Connell, J.M., Dominiczak, A.F., Junor, B.J., Briggs, J.D., Moss, J.G. Lancet (1997) [Pubmed]
  6. Expansion and fixation properties of a new braided biodegradable urethral stent: an experimental study in the rabbit. Vaajanen, A., Nuutinen, J.P., Isotalo, T., Törmälä, P., Tammela, T.L., Talja, M. J. Urol. (2003) [Pubmed]
  7. Current medical management of chronic stable angina. Thadani, U. J. Cardiovasc. Pharmacol. Ther. (2004) [Pubmed]
  8. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. Schömig, A., Kastrati, A., Dirschinger, J., Mehilli, J., Schricke, U., Pache, J., Martinoff, S., Neumann, F.J., Schwaiger, M. N. Engl. J. Med. (2000) [Pubmed]
  9. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. Grines, C.L., Cox, D.A., Stone, G.W., Garcia, E., Mattos, L.A., Giambartolomei, A., Brodie, B.R., Madonna, O., Eijgelshoven, M., Lansky, A.J., O'Neill, W.W., Morice, M.C. N. Engl. J. Med. (1999) [Pubmed]
  10. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. Leon, M.B., Baim, D.S., Popma, J.J., Gordon, P.C., Cutlip, D.E., Ho, K.K., Giambartolomei, A., Diver, D.J., Lasorda, D.M., Williams, D.O., Pocock, S.J., Kuntz, R.E. N. Engl. J. Med. (1998) [Pubmed]
  11. Treatment of ostial renal-artery stenoses with vascular endoprostheses after unsuccessful balloon angioplasty. Blum, U., Krumme, B., Flügel, P., Gabelmann, A., Lehnert, T., Buitrago-Tellez, C., Schollmeyer, P., Langer, M. N. Engl. J. Med. (1997) [Pubmed]
  12. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Walter, D.H., Schächinger, V., Elsner, M., Dimmeler, S., Zeiher, A.M. Lancet (1997) [Pubmed]
  13. Subacute thrombosis and vascular injury resulting from slotted-tube nitinol and stainless steel stents in a rabbit carotid artery model. Sheth, S., Litvack, F., Dev, V., Fishbein, M.C., Forrester, J.S., Eigler, N. Circulation (1996) [Pubmed]
  14. Experimental study of thrombogenicity and foreign body reaction induced by heparin-coated coronary stents. De Scheerder, I., Wang, K., Wilczek, K., Meuleman, D., Van Amsterdam, R., Vogel, G., Piessens, J., Van de Werf, F. Circulation (1997) [Pubmed]
  15. Long-term effects of intracoronary beta-radiation in balloon- and stent-injured porcine coronary arteries. Kałuza, G.L., Raizner, A.E., Mazur, W., Schulz, D.G., Buergler, J.M., Fajardo, L.F., Tio, F.O., Ali, N.M. Circulation (2001) [Pubmed]
  16. Acetylsalicylic acid in the prevention of early stenosis and occlusion of transjugular intrahepatic portal-systemic stent shunts: a controlled study. Theilmann, L., Sauer, P., Roeren, T., Otto, G., Arnold, J.C., Noeldge, G., Richter, G., Stiehl, A. Hepatology (1994) [Pubmed]
  17. Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation. Rupprecht, H.J., Darius, H., Borkowski, U., Voigtländer, T., Nowak, B., Genth, S., Meyer, J. Circulation (1998) [Pubmed]
  18. Four-year follow-up of Palmaz-Schatz stent revascularization as treatment for atherosclerotic renal artery stenosis. Dorros, G., Jaff, M., Mathiak, L., Dorros, I.I., Lowe, A., Murphy, K., He, T. Circulation (1998) [Pubmed]
  19. Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study. Ajzenberg, N., Aubry, P., Huisse, M.G., Cachier, A., El Amara, W., Feldman, L.J., Himbert, D., Baruch, D., Guillin, M.C., Steg, P.G. J. Am. Coll. Cardiol. (2005) [Pubmed]
  20. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). Serruys, P.W., Sianos, G., Abizaid, A., Aoki, J., den Heijer, P., Bonnier, H., Smits, P., McClean, D., Verheye, S., Belardi, J., Condado, J., Pieper, M., Gambone, L., Bressers, M., Symons, J., Sousa, E., Litvack, F. J. Am. Coll. Cardiol. (2005) [Pubmed]
  21. Reconstruction of stenotic or occluded iliofemoral veins and inferior vena cava using intravascular stents: re-establishing access for future cardiac catheterization and cardiac surgery. Ing, F.F., Fagan, T.E., Grifka, R.G., Clapp, S., Nihill, M.R., Cocalis, M., Perry, J., Mathewson, J., Mullins, C.E. J. Am. Coll. Cardiol. (2001) [Pubmed]
  22. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. Schömig, A., Neumann, F.J., Kastrati, A., Schühlen, H., Blasini, R., Hadamitzky, M., Walter, H., Zitzmann-Roth, E.M., Richardt, G., Alt, E., Schmitt, C., Ulm, K. N. Engl. J. Med. (1996) [Pubmed]
  23. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. Ochs, A., Rössle, M., Haag, K., Hauenstein, K.H., Deibert, P., Siegerstetter, V., Huonker, M., Langer, M., Blum, H.E. N. Engl. J. Med. (1995) [Pubmed]
  24. Intra-arterial stenting in the atherosclerotic rabbit. Robinson, K.A., Roubin, G.S., Siegel, R.J., Black, A.J., Apkarian, R.P., King, S.B. Circulation (1988) [Pubmed]
  25. Effects of endovascular radiation from a beta-particle-emitting stent in a porcine coronary restenosis model. A dose-response study. Carter, A.J., Laird, J.R., Bailey, L.R., Hoopes, T.G., Farb, A., Fischell, D.R., Fischell, R.E., Fischell, T.A., Virmani, R. Circulation (1996) [Pubmed]
  26. Benefit of an early invasive management strategy in women with acute coronary syndromes. Glaser, R., Herrmann, H.C., Murphy, S.A., Demopoulos, L.A., DiBattiste, P.M., Cannon, C.P., Braunwald, E. JAMA (2002) [Pubmed]
  27. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. O'Shea, J.C., Hafley, G.E., Greenberg, S., Hasselblad, V., Lorenz, T.J., Kitt, M.M., Strony, J., Tcheng, J.E. JAMA (2001) [Pubmed]
  28. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. O'Shea, J.C., Buller, C.E., Cantor, W.J., Chandler, A.B., Cohen, E.A., Cohen, D.J., Gilchrist, I.C., Kleiman, N.S., Labinaz, M., Madan, M., Hafley, G.E., Califf, R.M., Kitt, M.M., Strony, J., Tcheng, J.E. JAMA (2002) [Pubmed]
  29. Persistent systemic inflammatory response after stent insertion in patients with malignant bile duct obstruction. Ballinger, A.B., Woolley, J.A., Ahmed, M., Mulcahy, H., Alstead, E.M., Landon, J., Clark, M.L., Farthing, M.J. Gut (1998) [Pubmed]
  30. Interferon-gamma and interferon-gamma receptor 1 and 2 gene polymorphisms and restenosis following coronary stenting. Tiroch, K., von Beckerath, N., Koch, W., Lengdobler, J., Joost, A., Schömig, A., Kastrati, A. Atherosclerosis (2005) [Pubmed]
  31. Usefulness of preprocedural soluble CD40 ligand for predicting restenosis after percutaneous coronary intervention in patients with stable coronary artery disease. Türker, S., Güneri, S., Akdeniz, B., Ozcan, M.A., Baris, N., Badak, O., Kirimli, O., Yüksel, F. Am. J. Cardiol. (2006) [Pubmed]
  32. Vascular endothelial growth factor inhibits mitogen-induced vascular smooth muscle cell proliferation. Dorafshar, A.H., Angle, N., Bryer-Ash, M., Huang, D., Farooq, M.M., Gelabert, H.A., Freischlag, J.A. J. Surg. Res. (2003) [Pubmed]
  33. Tumor necrosis factor-alpha antibody eluting stents reduce vascular smooth muscle cell proliferation in saphenous vein organ culture. Javed, Q., Swanson, N., Vohra, H., Thurston, H., Gershlick, A.H. Exp. Mol. Pathol. (2002) [Pubmed]
  34. A scientific rationale for the CREST trial results: evidence for the mechanism of action of cilostazol in restenosis. Morishita, R. Atherosclerosis. Supplements. (2005) [Pubmed]
  35. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Serruys, P.W., van Hout, B., Bonnier, H., Legrand, V., Garcia, E., Macaya, C., Sousa, E., van der Giessen, W., Colombo, A., Seabra-Gomes, R., Kiemeneij, F., Ruygrok, P., Ormiston, J., Emanuelsson, H., Fajadet, J., Haude, M., Klugmann, S., Morel, M.A. Lancet (1998) [Pubmed]
  36. Drug-eluting stents in vascular intervention. Fattori, R., Piva, T. Lancet (2003) [Pubmed]
  37. Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Sauer, P., Theilmann, L., Stremmel, W., Benz, C., Richter, G.M., Stiehl, A. Gastroenterology (1997) [Pubmed]
  38. Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin, and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis. Makkar, R.R., Litvack, F., Eigler, N.L., Nakamura, M., Ivey, P.A., Forrester, J.S., Shah, P.K., Jordan, R.E., Kaul, S. Circulation (1997) [Pubmed]
WikiGenes - Universities